Zydus Lifesciences Limited
ZYDUSLIFE · ISIN: INE010B01027
Zydus Lifesciences Limited is a mid cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE010B01027.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 100 TRI (0.22%), NIFTY 500 TRI (0.15%), NIFTY LMC 250 TRI (0.11%)
CHART
Zydus Lifesciences Limited - growth of ₹100
Growth of ₹100 invested on 2026-09-30, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
+1.93%
3M
+5.11%
6M
+32.8%
1Y
+17.86%
3Y CAGR
+27.34%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Zydus Lifesciences Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-06-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-06-30.
F&O Sentiment
Nearest expiry: 2026-11-23 · As of 2026-10-28.
Corporate Actions
| Ex-Date | Type | Ratio | Details |
|---|---|---|---|
| 2015-10-06 | SPLIT | 0.200000 | FACE VALUE SPLIT (SUB-DIVISION) - FROM RS 5/- PER SHARE TO RE 1/- PER SHARE |
| 2010-04-05 | BONUS | 0.666667 | BONUS 1: 2 |
Recent Deals
No recent block/bulk/short-sell deals on record for this stock.
Frequently asked questions
What is Zydus Lifesciences Limited's 1-year and 3-year return?
Zydus Lifesciences Limited's 1-year price return is +17.86%. Its 3-year CAGR (annualized return) is +27.34%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Zydus Lifesciences Limited's latest financial performance?
Zydus Lifesciences Limited's trailing-twelve-month (TTM) revenue as of 2026-06-30 is ₹28,592 Cr, with a TTM profit after tax of ₹4,593 Cr and an EBITDA margin of 22.79%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹44.87, with a 5-year EPS growth rate of 25.45% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Zydus Lifesciences Limited's quality score?
Zydus Lifesciences Limited has a Punji quality score of 54.5 out of 100 as of 2026-06-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Zydus Lifesciences Limited's technical indicators show?
As of 2026-10-29, Zydus Lifesciences Limited's RSI (14-day) is 60.6 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Zydus Lifesciences Limited?
As of 2026-06-30, Zydus Lifesciences Limited's shareholding is split across Promoter (75.01%), Public (24.99%). Promoter holding of 75.01% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Zydus Lifesciences Limited part of any major market index?
Yes - Zydus Lifesciences Limited is a constituent of NIFTY 100 TRI (0.22% weight) and NIFTY 500 TRI (0.15% weight) and NIFTY LMC 250 TRI (0.11% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
What does the F&O market show for Zydus Lifesciences Limited?
As of 2026-10-28 (nearest expiry 2026-11-23), Zydus Lifesciences Limited's put-call ratio by open interest is 0.6474 - below 1, typically read as bullish positioning (more open interest on calls than puts). The max pain strike is ₹1160, the price at which option writers as a group would owe the least to option buyers at expiry - a reference level some traders watch, not a price target. F&O positioning reflects derivatives-market sentiment over a specific expiry window, not a fundamental view on the company.
What corporate actions has Zydus Lifesciences Limited announced recently?
The most recent corporate action for Zydus Lifesciences Limited is a SPLIT (0.200000) with an ex-date of 2015-10-06, for: FACE VALUE SPLIT (SUB-DIVISION) - FROM RS 5/- PER SHARE TO RE 1/- PER SHARE. The ex-date is the cutoff - only shareholders who held the stock before this date qualify for the action (dividend, split, bonus, or rights issue, depending on type). Corporate actions typically adjust the stock's price and/or share count mechanically on the ex-date, which is why historical price charts are usually shown adjusted for these events.
Stock data · Not financial advice · Past performance does not indicate future returns